Evidence map›Paper›PMID 30720112›Full record

ArticleInternational journal of oncology2019

Upregulation of microRNA‑194‑5p inhibits hypopharyngeal carcinoma cell proliferation, migration and invasion by targeting SMURF1 via the mTOR signaling pathway.

Shan Xu, Lian Hui, Ning Yang, Yan Wang, Ning Zhao, Xue-Jun Jiang

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shan XuDepartment of Ear, Nose and Throat, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Lian HuiDepartment of Ear, Nose and Throat, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Ning YangDepartment of Ear, Nose and Throat, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Yan WangDepartment of Ear, Nose and Throat, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Ning ZhaoDepartment of Ear, Nose and Throat, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Xue-Jun JiangDepartment of Ear, Nose and Throat, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
China Medical University · CNFirst Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypopharyngeal carcinoma (HPC) is an aggressive malignancy with the worst prognosis among all head and neck cancers. MicroRNAs (miRNAs) are involved in the development of many human cancers, and may function as oncogenes or tumor suppressors. The present study aimed to evaluate the effects of miRNA (miR)‑194‑5p on the proliferation and invasion of HPC cells and to identify the potential regulatory mechanism. First, miR‑194‑5p and Smad ubiquitin regulatory factor 1 (SMURF1) expression levels were examined in HPC tissues. Subsequently, to explore the effects of miR‑194‑5p on SMURF1, a dual‑luciferase reporter gene assay was performed to verify the target relationship. To define the role of miR‑194‑5p in HPC progression, miR‑194‑5p upregulation and depletion were used to evaluate its effects on cell viability, invasion and migration. SMURF1 silencing and rapamycin [an inhibitor of the mammalian target of rapamycin (mTOR) signaling pathway] treatment were also used to analyze the regulatory mechanism in HPC. Finally, tumor growth was assessed in xenografted tumors in nude mice. SMURF1 was demonstrated to be highly expressed, whereas miR‑194‑5p was poorly expressed in HPC tissues; SMURF1 was identified as a target gene of miR‑194‑5p. FaDu hypopharyngeal squamous cell carcinoma cells treated with miR‑194‑5p mimics exhibited decreased viability, invasion and migration. The results indicated that miR‑194‑5p may inactivate the mTOR signaling pathway by targeting SMURF1. In addition, the in vivo experiments further verified these regulatory effects. These data suggested that miR‑194‑5p‑targeted SMURF1 inhibition may be involved in the disruption of HPC progression through the repression of the mTOR signaling pathway.

Indexed as

Up-Regulation3' Untranslated RegionsAgedAnimalsCarcinoma, Squamous CellCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansHypopharyngeal NeoplasmsMaleMiceMicroRNAsMiddle Aged3' Untranslated RegionsMicroRNAsMIRN194 microRNA, humanMTOR protein, humanSirolimusSMURF1 protein, humanTOR Serine-Threonine KinasesUbiquitin-Protein Ligaseshypopharyngeal carcinomamammalian target of rapamycin signaling pathwaymetastasismicroRNA-194-5pproliferationSmad ubiquitin regulatory factor 1

Identifiers

PMID30720112
PMCPMC6411369
OpenAlexW2911612760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.